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Background
Enfurvitide (T-20) is, besides zidovudine, the only HIV
drug that does not have to be given orally. Systemic side-
effects are rare and there are no known important interac-
tions. Enfurvitide is approved in Sweden for triple class
experienced patients with treatment failure or intolerance
to other antiretroviral drugs (ART). In reality there have
been other reasons for choosing enfurvitide.
Methods
A retrospective analysis was performed of all patients
treated with enfurvitide in our clinic from 2004 to January
2008 in a patient population of 755 HIV-positive patients
of whom 73% were on ART.
Summary of results
A total of 25 patients had received treatment with enfur-
vitide. In 10 cases the indication was triple failure. In eight
cases the indication was intolerance to other ARTs, in one
case "induction therapy" for a patient with high VL and
resistance, and in one case for prevention of mother-to-
child transmission. Five cases were severely ill patients in
need of parenteral administration of drugs, complicated
medication and/or repeated surgical interventions (see
Table 1).
In all patients T-20 was combined with one or two other
antiretrovirals. The reduced risk for interactions facilitated
treatment of concomitant disorders. The parenteral
administration also made it possible to maintain ART dur-
ing ICU care or introduce effective ART earlier than other-
wise had been possible. As a further benefit the reduced
viral load reduced the risk for HIV transmission to staff
during surgery and care in the ICU.
Conclusion
The indications for enfurvitide were in 28% of cases (7/25
cases) other than failure or intolerance and most com-
monly severely ill patients with co-morbidities in need for
treatment interacting with conventional ARTs. The
parenteral administration, lack of interaction and antiret-
roviral effect made it possible to maintain undetectable
viral load in HIV-treated patients hospitalised for medical
or surgical emergencies, and to rapidly reduce viral load in
newly diagnosed patients during ICU-care. This can
improve the chances for survival for the patients and also
reduce the risk for transmission to the staff.
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nr Sex/Age Concomitant illness CD4 VL at start Days on T-20 Outcome
1 f/36 Abdominal trauma, repeated surgery, bleeding 280 <5 80 Dead
2 f/46 Advanced AIDS, enteric administration difficult. 50 2300 102 Dead
3 f/35 TB and Pneumocystosis. 110 7600 296 Succesfull. Stopped T-20 when TB-
treatment was finished.
4 m/52 Severe pneumonia and cardiac arrest 110 <50 12 Successful. Restarted previous ART 
after improvement.
5 f/52 HIV with severe immunodeficiency diagnosed in 
ICU when treated for fasciitis and septicaemia
40 792000 19 Successful. Changed to NNRTI based 
ART after improvemePage 2 of 2
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